SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2020 after market close on Monday, May 4, 2020. SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain.
Ladies and gentlemen, thank you for standing by, and welcome to the SI-BONE first-quarter 2020 operating results conference call. Joining me today are Jeff Dunn, president and chief executive officer; and Laura Francis, chief financial officer and chief operating officer of SI-BONE. Earlier today, SI-BONE released financial results for the quarter ended March 31, 2020.
There's been a notable change in appetite for SI-BONE, Inc. (NASDAQ:SIBN) shares in the week since its full-year...
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2019 after market close on Monday, March 9, 2020. SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain.
SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the company will be participating in the upcoming Bank of America Securities 2020 Health Care Conference that is being held virtually. SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain.
SI-BONE, Inc., (SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that CIGNA has established a positive coverage policy for minimally invasive SI joint fusion. The new policy specifies that coverage will be exclusive for FDA cleared implants that are placed across the SI joint and intended to promote bone fusion. This decision follows an extensive amount of published clinical evidence demonstrating the safety and effectiveness of the iFuse Implant System, including a recent publication of 5-year results from a long-term prospective study called LOIS (Long Term Outcomes from INSITE and SIFI).
SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today provided an update on the actions it is taking to support patients, customers, and employees while maintaining business continuity in response to the coronavirus (COVID-19) pandemic. Protecting Employees and Others: To reduce the risk to SI-BONE employees and their families from potential exposure to COVID-19, all employees in the Santa Clara office and in other office locations have been required to work from home, with the exception of those related to manufacturing order fulfillment and select others, based on local restrictions and guidance. SI-BONE has also restricted non-essential business travel, and urged employees to restrict personal travel, to protect the health and safety of its employees, patients and customers.
SANTA CLARA, Calif., March 09, 2020 -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Si-Bone (SIBN) delivered earnings and revenue surprises of -30.56% and -6.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The analysts covering SI-BONE, Inc. (NASDAQ:SIBN) delivered a dose of negativity to shareholders today, by making a...
SANTA CLARA, Calif., Jan. 22, 2020 -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE”), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
In addition, SI-BONE expects to grant the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock on the same terms and conditions. Of the shares of common stock being offered, 1,809,947 shares are being offered by selling stockholders and 2,490,053 shares are being offered by SI-BONE. Morgan Stanley and BofA Securities are acting as joint book-running managers.
SI-BONE, Inc. (SIBN) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, SI-BONE is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting. The previously announced date and time of the Annual Meeting, Tuesday, June 16, 2020, at 10:00 a.m. Pacific Time, as disclosed in the previously distributed Notice of the Annual Meeting and Definitive Proxy Statement, has not changed.
NEW YORK, NY / ACCESSWIRE / March 9, 2020 / SI-BONE, Inc. (SIBN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 9, 2020 at 4:30 PM Eastern Time. ...
SI-BONE, Inc. (NASDAQ:SIBN) just released its latest quarterly report and things are not looking great. It was a...
SI-BONE, Inc. (SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the fourth quarter and full year 2019. Preliminary and unaudited revenue for fourth quarter 2019 is expected to be in the range of $19.5-$19.8 million, reflecting growth of 25-27% compared to the prior year period. International revenue is expected to be in the range of $1.2-$1.3 million.
SANTA CLARA, Calif., May 04, 2020 -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today.